Skip to main
ACAD

ACADIA Pharma (ACAD) Stock Forecast & Price Target

ACADIA Pharma (ACAD) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 40%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

ACADIA Pharmaceuticals is a promising biopharmaceutical company with a focus on neurological and rare diseases. The success of its commercial products, NUPLAZID and DAYBUE, as well as the potential of remlifanserin in treating Alzheimer's and Lewy body-associated psychosis, make it a strong player in the market. However, ongoing debates about the efficacy of remlifanserin highlight the risk of investing in the company.

Bears say

ACADIA Pharmaceuticals is currently facing challenges that may have a negative impact on its stock performance. Despite being in the rare and neurological diseases market, the company's main product NUPLAZID may face competition from emerging assets like Cobenfy. Additionally, while its clinical-stage development efforts show potential, these programs are still in early stages and may not yield positive results. Furthermore, recent data from its phase 3 trial for Alzheimer's disease psychosis showed that the drug's efficacy was disproportionately better in one subgroup, leading to concerns about its overall effectiveness. The stock's risk/reward is upside-biased, but downside risks may include lack of commercial success for its rare disease drug and new safety issues emerging.

ACADIA Pharma (ACAD) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 40% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ACADIA Pharma (ACAD) Forecast

Analysts have given ACADIA Pharma (ACAD) a Buy based on their latest research and market trends.

According to 15 analysts, ACADIA Pharma (ACAD) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ACADIA Pharma (ACAD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.